Table 1 Study Characteristics
Study | Year | Country | No. of cases | Follow-up (months) | Site | Surgery | Quality Score | |
|---|---|---|---|---|---|---|---|---|
Denosumab | Control | |||||||
Agarwal(19) | 2018 | India | 25 | 34 | 12 to 24 | E/K | C/W | ******** |
Chen(15) | 2018 | China | 20 | 10 | 3 to 36 | K | Unspecified | ***** |
Costantino(3) | 2018 | Italy | 25 | 222 | > 24 | E/K | C | ****** |
Liu(18) | 2016 | China | 1 | 3 | > 8 | E | C | **** |
Medellin(20) | 2018 | UK | 7 | 100 | > 12 | E | C/W | ****** |
Scoccianti(9) | 2018 | Italy | 12 | 9 | 14 to 92 | E/K | C | ****** |
Tsukamoto(13) | 2019 | Japan | 25 | 317 | 54 to 124 | E/K | C/W | ****** |
Urakawa(17) | 2018 | Japan | 40 | 158 | 60 to 72 | E/K | C | ***** |
Yang(22) | 2018 | China | 6 | 10 | > 24 | K | C/W | ******** |
Zou(21) | 2018 | China | 8 | 50 | 21 to 321 | K | C/W | ****** |